Accedi

National Cancer Center Japan

1 ARTICLES PUBLISHED IN JoVE

Immunological Elimination of Undifferentiated Human Pluripotent Stem Cells Using Pluripotent State-Specific Antigen, Glypican-3

Marina Okada¹, Shugo Tohyama¹, Jun Fujita¹, Tetsuya Nakatsura², Keiichi Fukuda¹

¹Department of Cardiology, Keio University School of Medicine, ²Division of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center Japan

Regenerative therapies using human induced pluripotent stem cells (hiPSCs) have recently attracted much attention. In this study, we use anticancer immunotherapy with peptide vaccination to prevent hiPSC-derived tumorigenesis. Our results show that glypican-3 (GPC3) works as a pluripotent state-specific immunogenic antigen in hiPSCs.